Drug Profile
Elomotecan
Alternative Names: BN 80927; R 1559Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Ipsen
- Class Antineoplastics; Camptothecins
- Mechanism of Action DNA topoisomerase I inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
- Discontinued Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in European Union (IV, Infusion)
- 08 Jun 2010 Adverse events, pharmacokinetics and efficacy data from a phase I trial in Solid tumours presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO-2010)
- 22 Mar 2007 Elomotecan is still in phase I trials for Solid tumours in European Union